Single-Dose Pharmacokinetics of Amphetamine Extended-Release Oral Suspension in Healthy Adults.

Related Articles

Single-Dose Pharmacokinetics of Amphetamine Extended-Release Oral Suspension in Healthy Adults.

J Atten Disord. 2019 Apr 26;:1087054719841131

Authors: Herman BK, Bouhajib M, King TR, Kando JC, Pardo A

Abstract
PURPOSE: This single-dose pivotal study evaluated the pharmacokinetics of amphetamine extended-release oral suspension (AMPH EROS) under fasted and fed conditions and the relative bioavailability of AMPH EROS and immediate-release mixed amphetamine salts (IR MAS) in adults.
METHODS: This open-label, randomized, three-period, three-treatment, six-sequence crossover study enrolled 30 healthy adult participants who were randomly assigned to receive either 1 dose of AMPH EROS 18.8 mg under fed or fasted conditions or 30 mg of IR MAS under fasted conditions. Participants crossed over with a 7-day washout period between each of the three periods. Plasma samples were measured for Cmax, AUC0- t, AUC0-5, AUC5- t, and AUC0-∞ for comparative bioavailability.
RESULTS: The geometric mean ratios for Cmax, AUC0- t, and AUC0-∞ were within the 90% confidence limits [80.0%, 125.0%] for comparable bioavailability. There was no food effect for AMPH EROS. Both the AMPH EROS and IR MAS formulations were generally well tolerated with no serious adverse events reported.
CONCLUSIONS: The bioavailability of a single dose of AMPH EROS was comparable to two 15 mg doses of IR MAS, given 4 hr apart, with no food effect or safety concerns observed.

PMID: 31027435 [PubMed – as supplied by publisher]

via https://www.ncbi.nlm.nih.gov/pubmed/31027435?dopt=Abstract